Nevertheless, given the at best modest inhibitory effects of JNK inhibition on bulk tumor growth shown in the study [21] and in the present study, apparently, it is essential that future JNK-targeting therapies against pancreatic cancers be combined with other treatment modalities aimed at the tumor bulk. The gene discussed is MAPK8; the disease is neoplasm.